Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 42.95 |
| Open | 43.49 |
| Bid | 45.00 x N/A |
| Ask | 46.00 x N/A |
| Day's Range | 43.00 - 48.00 |
| 52 Week Range | 6.50 - 48.00 |
| Volume | 11,936,007 |
| Avg. Volume | 3,183,755 |
| Market Cap | 301.231M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.20 |
| Earnings Date | Jun 21, 2021 - Jun 25, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Simply Wall St.
How Much Of Open Orphan plc (LON:ORPH) Do Insiders Own?
If you want to know who really controls Open Orphan plc ( LON:ORPH ), then you'll have to look at the makeup of its...
Yahoo FinanceCoronavirus update: Biden administration increases vaccine doses to states; UK approves first human challenge trial
Federal government increasing state allotment of vaccines. Meanwhile, U.K. begins first human challenge trials.
- Business Wire
Ethics Approval Granted for Open Orphan’s COVID-19 Human Challenge Study Model
Open Orphan (AIM:ORPH) announced the world’s first COVID-19 characterization study has received ethics approval in the UK.
© 2021 Verizon Media. All rights reserved.
